Serum glial fibrillary acidic protein

Overview

Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein expressed predominantly by astrocytes in the central nervous system (CNS). It serves as a structural component of the astrocytic cytoskeleton and plays a fundamental role in maintaining cellular integrity, supporting myelination, and mediating responses to CNS injury. When astrocytes are damaged, stressed, or undergo reactive gliosis, GFAP is released into the extracellular space and subsequently enters the bloodstream, making serum and plasma GFAP (sGFAP) a measurable surrogate of astrocytic injury and neurodegeneration. Its elevation in peripheral blood reflects diverse CNS pathologies, ranging from acute traumatic brain injury to chronic neurodegenerative and neuroinflammatory diseases.

As a fluid biomarker, sGFAP has attracted substantial interest due to advances in ultrasensitive immunoassay platforms that enable reliable quantification at sub-picogram-per-milliliter concentrations in blood. Unlike invasive cerebrospinal fluid sampling, blood-based GFAP measurement offers a practical, scalable approach for disease monitoring, prognostication, and therapeutic response assessment. Its utility spans multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (mTBI), epilepsy, HIV-associated neurocognitive disorders, and aging-related cognitive decline, positioning sGFAP as one of the most broadly applicable CNS biomarkers in contemporary translational neuroscience.

Focus of Latest Publications

Recent investigations demonstrate serum glial fibrillary acidic protein (sGFAP) as a sensitive biomarker reflecting astrocytic activation and neuroinflammation across acute and chronic central nervous system pathology. Studies evaluated sGFAP across acute traumatic and ischemic brain injury, progressive neurological conditions including multiple sclerosis and amyotrophic lateral sclerosis, and neurodegenerative diseases such as Alzheimer's disease. Research employed diverse immunoassay platforms including traditional laboratory-based methods, automated chemiluminescent systems, and point-of-care nanophotonic biosensors integrated with artificial intelligence-assisted analysis, enabling quantification in serum, plasma, and capillary blood samples for diagnostic and prognostic applications.

In acute brain injury, sGFAP shows clinical promise for both diagnostic exclusion and prognostic stratification. In mild traumatic brain injury, serum GFAP combined with ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), measured within 12 hours of injury, effectively ruled out computed tomography-detectable intracranial lesions in emergency department populations, with potential to reduce unnecessary neuroimaging and radiation exposure. In acute ischemic stroke cohorts, serum GFAP levels were significantly elevated compared to controls with a characteristic temporal pattern peaking at 48–72 hours post-symptom onset. Elevated admission GFAP concentrations independently predicted poor functional outcomes at three months and shorter long-term survival, and elevated levels correlated with hemorrhagic transformation and systemic infection complications including pneumonia.

In chronic progressive neurological conditions, sGFAP tracks astrocytic activation related to disease progression and comorbidities. Multiple sclerosis studies demonstrated that sGFAP remained stable during immunotherapy transitions from intravenous to subcutaneous natalizumab, supporting continuity of CNS injury monitoring during treatment changes. Serum GFAP in combination with retinal structural markers from optical coherence tomography provided additive prognostic value for predicting disability progression independent of clinical relapse activity. In amyotrophic lateral sclerosis, plasma GFAP defined a distinct biological axis characterized primarily by association with age and behavioral lability, complementing neurofilament light chain (reflecting upper motor neuron burden) and phosphorylated tau-181 (reflecting lower motor neuron degeneration). In Alzheimer's disease and related cognitive impairment, sGFAP correlated with cognitive performance and functional status, and capillary blood self-collection methods now enable point-of-care screening to triage individuals at varying risk of cognitive decline in community settings.

Beyond individual conditions, evidence supports GFAP's utility as a complementary biomarker integrated with other CNS injury markers. In temporal lobe epilepsy, sGFAP levels were elevated in patients with comorbid depression compared to those with epilepsy alone, suggesting astroglial activation linked to psychiatric comorbidity. In acute ischemic stroke, multiplex biomarker panels incorporating GFAP, S100B, and UCH-L1 achieved improved diagnostic accuracy for differentiating stroke subtypes. Technical advances including nanophotonic heterochain biosensors with deep learning-integrated image analysis, portable smartphone-based detection platforms, and fully automated chemiluminescent immunoassays have enhanced assay sensitivity and accessibility. Standardized preanalytical handling protocols and reference ranges in healthy adult populations have been established, supporting integration of GFAP testing into evidence-based clinical pathways for emergency and outpatient management of acute and chronic CNS conditions.

Key Publications

• NEWJul Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas. (Pituitary, 2026, PMID 42384349): "We investigated whether postoperative changes in glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and tau are associated with fatigue and cognitive outcomes in patients with nonfunctioning pituitary adenomas (NFPAs)."
• NEWJun Blood-based biomarkers GFAP/UCH-L1 for the diagnosis of mild traumatic brain injury (mTBI): a single-center implementation experience. (European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2026, PMID 42340459): "GFAP (glial fibrillary acidic protein) and UCH-L1 (ubiquitin carboxyl-terminal hydrolase-L1) turned out to be potential biomarkers for the diagnosis of mTBI."
• NEWJun Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. (Journal of neurology, 2026, PMID 42332277): "Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are sensitive biomarkers of neuroaxonal damage and astroglial activation."
• NEWJun Study protocol for investigating real-world implementation of a combined glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) blood test in the management of adult mild traumatic brain injury in a single-centre European emergency department: the IMPACTS-BRAINI study. (BMJ open, 2026, PMID 42315262): "Glial fibrillar acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) have been shown to rule out CT-detectable intracranial lesions in patients with mild traumatic brain injury (mTBI) when assessed within the first 12 hours after injury."
• NEWJun Temporal Pattern and Clinical Value of Serum GFAP in Acute Ischemic Stroke: Results from Two Prospective German Cohorts. (Translational stroke research, 2026, PMID 42295622): "Serum glial fibrillary acidic protein (sGFAP) is an astroglial biomarker preliminarily investigated in acute ischemic stroke (AIS)."
• May Plasma central nervous system biomarkers in heavily treatment-experienced people with HIV in the PRESTIGIO registry. (AIDS (London, England), 2026, PMID 42207142): "Biomarkers included NFL, t-Tau, GFAP, and UCH-L1."
• May Differences in Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Tau Protein Levels in Patients with Temporal Lobe Epilepsy and Comorbid Depression. (Molecular neurobiology, 2026, PMID 42189430): "In the overall sample, plasma GFAP levels were highest in the TLE-D group, intermediate in the TLE group, and lowest in the HC group, with age identified as a significant covariate (B=0.007, P=0.035)."
• Jun AI-Enhanced Nanophotonic Heterochain Sensor Enables Multiplexed Biomarker Detection across Serum, Urine, and Saliva for Stroke Differentiation. (ACS applied bio materials, 2026, PMID 42166366): "Methods: We developed a nanophotonic heterochain biosensing platform integrated with deep learning-assisted image analysis for multiplex detection of S100B, GFAP, and UCH-L1 in serum, urine, and saliva."
• May Adverse outcome pathway-based analysis of vanillic acid-induced neurodevelopmental toxicity and cellular senescence in zebrafish. (Ecotoxicology and environmental safety, 2026, PMID 42161108): "At the molecular level, VA exposure affected the expression of multiple key genes involved in nervous system, sensory organ development and cellular senescence, such as gfap, pomca, bdnf, s100b, insm1a, mbpa, p21, and telom."
• May Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis. (Neurology(R) neuroimmunology & neuroinflammation, 2026, PMID 42127333): "Serum glial fibrillary acidic protein (sGFAP) is a promising astrocytic biomarker to capture disease progression in pwMS."